Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST

Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-media...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotzur, Rebecca, Stein, Natan, Kahlon, Shira, Berhani, Orit, Isaacson, Batya, Mandelboim, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440710/
https://www.ncbi.nlm.nih.gov/pubmed/37609636
http://dx.doi.org/10.1016/j.isci.2023.107284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440710/
https://www.ncbi.nlm.nih.gov/pubmed/37609636
http://dx.doi.org/10.1016/j.isci.2023.107284

Ejemplares similares